Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]
Discontinued
Reference number: GID-TAG507
The company have requested the opportunity to make a further submission including a patient access scheme, which will be reviewed by the evidence review group (ERG). The company submission and the ERG’s review will be considered at a committee meeting discussion on 26 May 2016.